American Pharmaceutical Partners(Schaumburg, Ill) recently received FDA approval for its abbreviated new drug application for Azithromycin for Injection. The product is the generic equivalent of Pfizer Inc's Zithromax. Azithromycin for Injection is indicated for the treatment of community-acquired pneumonia and pelvic inflammatory disease, when caused by susceptible microorganisms. The product will be available in 500-mg vials. Azithromycin for Injection is preservative-free, and each vial will include a bar code and latex-free vial stopper. For more information, visit www.appdrugs.com.
The Oncology Care Pharmacist in Health-System Pharmacy
According to the National Cancer Institute, almost 40% of men and women will be given a diagnosis of some form of cancer in their lifetime.
News from the year's biggest meetings
Clinical features with downloadable PDFs